natgillin/translations-raw huggingface dataset:
Oral: Ethinyloestradiol+Norgestimate/Efavirenz (0.035 mg+0.25 mg q.d./600 mg q.d.)
Peroralno: etinilestradiol+norgestimat/efavirenz (0,035 mg+0,25 mg dnevno/600 mg d nevno)
Orally administered enoxaparin is poorly absorbed and even large doses should not lead to any serious consequences.
Peroralno aplicirani enoksaparin se slabo absorbira, zato celo veliki peroralni odmerki ne bi smeli imeti resnih posledic.
Orally administered imiquimod is rapidly and extensively metabolised into two main metabolites.
Peroralno uporabljen imikvimod se hitro in obsežno presnavlja v dva glavna metabolita.
Orally administered midazolam (2.5 mg once daily), tenofovir alafenamide (25 mg once daily)
peroralno uporabljen midazolam (2,5 mg enkrat dnevno), alafenamidtenofovirat (25 mg enkrat dnevno)
Orally administered midazolam (2.5 mg single dose)/ Tenofovir alafenamide (25 mg once daily)
Peroralno uporabljen midazolam (2,5 mg enkratni odmerek)/alafenamidtenofovirat (25 mg enkrat dnevno)
Orally administered Tecfidera (dimethyl fumarate) undergoes rapid presystemic hydrolysis by esterases and is converted to its primary metabolite, monomethyl fumarate, which is also active.
Peroralno uporabljeno zdravilo Tecfidera (dimetilfumarat) je predmet hitre predsistemske hidrolize z esterazami, kjer se pretvori v svoj najpomembnejši presnovek, monometil fumarat, ki je prav tako aktiven.
orally BID in patients less than
BID pri bolnikih, lažjih od
Orange cap imprinted with “R” & flesh color body imprinted with “6”
Kapa oranžne barve z natisnjenim napisom »R« in telo svetlo rjave barve z natisnjenim napisom »6«.
Orange cap off
Snet oranžni pokrovček
Orange colour cap imprinted with “R” & orange color body imprinted with “4.5”
Kapa oranžne barve z natisnjenim napisom »R« in telo oranžne barve z natisnjenim napisom »4,5«.
Orange film-coated tablets debossed with “GSK” on one side and "4" on the other side.
Oranžne filmsko obložene tablete, označene z “GSK” na eni in “4” na drugi strani.
Orange marked “Pfizer” on the cap and “PGN 100” on the body with black ink.
Oranžna kapsula, ki ima na pokrovčku kapsule s črnim črnilom izpisano oznako “Pfizer”, na telesu kapsule pa “PGN 100”
Orange opaque/ Orange opaque, size “1” hard gelatin capsules imprinted with ‘PG’ on cap and ‘200’ on body.
Neprozorne oranžne/neprozorne oranžne trde želatinske kapsule velikosti “1”, ki imajo na pokrovčku natisnjeno oznako “PG”, na telesu pa “200”.
Orange opaque/ White opaque, size “1” hard gelatin capsules imprinted with ‘PG’ on cap and ‘225’ on body.
Neprozorne oranžne/neprozorne bele trde želatinske kapsule velikosti “1”, ki imajo na pokrovčku natisnjeno oznako “PG”, na telesu pa “225”.
Orange opaque/Orange opaque, size “1” hard gelatin capsules, imprinted with ‘PG’ on cap and ‘200’ on body.
Neprozorne oranžne/neprozorne oranžne trde želatinske kapsule velikosti “1”, ki imajo na pokrovčku natisnjeno oznako “PG”, na telesu pa “200”.
Orange opaque/White opaque, size “1” hard gelatin capsules, imprinted with ‘PG’ on cap and ‘225’ on body.
Neprozorne oranžne/neprozorne bele trde želatinske kapsule velikosti “1”, ki imajo na pokrovčku natisnjeno oznako “PG”, na telesu pa “225”.
Orange vanilla flavour
aharoza aroma pomaranče in vanilije
Orange, almond-shaped 5 x 8.4 mm film-coated tablet marked with “TL” on one side and “15” on the other side.
Oranžna filmsko obložena tableta mandljaste oblike velikosti 5 x 8,4 mm, z vtisnjeno oznako "TL" na eni strani in "15" na drugi strani.
Orange, capsule shaped, biconvex film-coated tablet – engraved with “L 100” on one side and plain on the other.
Oranžna, bikonveksna, filmsko obložena tableta v obliki kapsule, z vtisnjeno oznako »L 100« na eni strani in gladka na drugi.
Orange, capsule shaped, biconvex film-coated tablet – engraved with “L100” on one side and plain on the other
Oranžna, bikonveksna, filmsko obložena tableta v obliki kapsule, z vtisnjeno oznako »L 100« na eni strani in gladka na drugi.
Orange, round, biconvex film-coated tablet of 10 mm diameter, engraved with the Santhera logo on one side and ‘150’ on the other side.
Oranžna, okrogla, bikonveksna filmsko obložena tableta s premerom 10 mm ter logotipom Santhera na eni strani in »150« na drugi.
Orange, round-shaped film-coated tablets (6.7 mm diameter) debossed with “DSC L15”.
Oranžne, okrogle filmsko obložene tablete, premera 6,7 mm, z vtisnjenim napisom “DSC L15”.
Orange-white, oval, biconvex, film-coated tablets, embossed with “125” on one side.
Tracler 125 mg filmsko obložene tablete oranžnobela, ovalne, na obeh straneh izbočena filmsko obložena tableta, ki ima na eni strani vtisnjeno “125”.
Orange-white, round, biconvex, film-coated tablets, embossed with “62,5” on one side.
STAYVEER 62,5 mg filmsko obložene tablete oranžnobela, okrogla, na obeh straneh izbočena filmsko obložena tableta, ki ima na eni strani vtisnjeno “62,5”.
Orange-yellowish semi-transparent frozen suspension.
Oranžno-rumenkasta pol prozorna zmrznjena suspenzija.
Orbactiv 400 mg powder for concentrate for solution for infusion.
Orbactiv 400 mg prašek za koncentrat za raztopino za infundiranje
Orbactiv is a powder for concentrate for solution for infusion
Zdravilo Orbactiv je prašek za koncentrat za raztopino za infundiranje.
Orbactiv is a white to off white powder, supplied in a 50 ml glass vial.
Zdravilo Orbactiv je bel do belkast prašek v 50 ml stekleni viali.
Orbactiv is an antibiotic that contains the active substance oritavancin.
Zdravilo Orbactiv je antibiotik ki vsebuje zdravilno učinkovino oritavancin.
Orbactiv is available in cartons containing 3 vials.
Zdravilo Orbactiv je na voljo v pakiranjih po 3 viale.
Orbactiv is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4.4 and 5.1).
Zdravilo Orbactiv je indicirano za zdravljenje akutnih bakterijskih okužb kože in kožnih struktur (ABSSSI, acute bacterial skin and skin structure infections) pri odraslih (glejte poglavji 4.4 in 5.1).
Orbactiv is intended for intravenous (IV) administration, only after reconstitution and dilution.
Zdravilo Orbactiv je namenjeno intravenskemu (i.v.) dajanju po rekonstituciji in redčenju.
Orbactiv may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading.
Zdravilo Orbactiv lahko vpliva na laboratorijske teste, ki merijo strjevanje krvi, in povzroči lažne rezultate.
Orbactiv should not to be used in children or adolescents.
Otroci in mladostniki ne smejo uporabljati zdravila Orbactiv.
Orbifloxacin 8.5 mg/ML
Orbifloksacin 8.5 mg/ml
Orbifloxacin 8.5 mg/ml Mometasone furoate (as monohydrate) 0.9 mg/ml
Orbifloksacin 8.5 mg/ml Mometazon furoat (kot monohidrat) 0.9 mg/ml
Orbifloxacin – Summary
Orbifloksacin – Povzetek
orbitol special-glycerin blend (glycerin, sorbitol, sorbitol anhydrides (1,4-sorbitan), mannitol and water) titanium dioxide (E171) printing ink (SDA 35A alcohol (ethanol & ethyl acetate), propylene glycol (E1520), iron oxide black (E172), polyvinyl acetate phthalate, purified water, isopropyl alcohol, macrogol 400, ammonium hydroxide 28%)
zmes sorbitola in posebenega glicerola (glicerol, sorbitol, sorbitol anhidridi (1,4-sorbitan), manitol in voda) titanov dioksid (E171) tiskarsko črnilo (alkohol SDA 35A (etanol & etilacetat), propilenglikol (E1520), črni železov oksid (E172), polivinilacetat ftalat, prečiščena voda, izopropilalkohol, makrogol 400, amonijev hidroksid 28 %)
ORe (95% CI)=1.428 (0.749; 2.722)
ORe (95% CI)=1,428 (0,749;
ORe (95% CI)=1.428 (0.749; 2.722) p-valueg=0.275
ORe (95% CI)=1,428 (0,749; 2,722) p-vrednostg=0,275
ORe (95% CI)=1.688 (1.148; 2.481) p-valueg=0.007
ORe (95 % CI)=1,688 (1,148; 2,481) p-vrednostg=0,007
ore in the mouth or on lips
razjeda v ustih ali na ustnicah
ore mouth
vneta usta,
ore mouth (stomatitis)
vnetje v ustih (stomatitis),
ore mouth (stomatitis) pain in the stomach area under the ribs.
vnetje v ustih (stomatitis) bolečine v predelu želodca pod rebri.
ore mouth or lip, throat pain
vnetje ust ali ustnic, bolečina v žrelu
ore mouth, throat or mouth ulcers
vnetje ust, grla ali razjede v ustih;
ore mouth/mouth ulcers
vnetje/razjede ustne sluznice,
ore on the skin of the penis
razjede na koži penisa
ore or painful joints
vneti ali boleči sklepi,
ore or runny nose, sore sinuses mouth or tongue ulcers
vnetje nosne sluznice ali izcedek iz nosu, vnetje sinusov razjede v ustih ali na jeziku
ore skin
boleča koža
ore throat
vnetje žrela
ore throat
vnetje žrela in grla
ore throat
vnetje žrela,
ore throat
vneto grlo
ore throat
vneto žrelo,
ore throat and discomfort when swallowing gastrointestinal symptoms such as vomiting and diarrhoea
vnetje žrela in težave pri požiranju prebavni simptomi, kot sta bruhanje in driska
ore throat and discomfort when swallowing, inflammation of the lungs, sinuses, tonsils, nose and throat
vnetje žrela in težko požiranje, pljučnica, vnetje sinusov, mandeljnov, nosu in žrela
ore throat or burning sensation when passing water severe stomach pain, fever and possibly diarrhoea (rarely with blood in it) - these can be signs of bowel inflammation (neutropenic colitis).
vnetje žrela ali pekoč občutek med uriniranjem; huda bolečina v želodcu, povišana telesna temperatura in lahko tudi driska (redko krvava), kar so lahko znaki vnetja črevesja (nevtropeničnega kolitisa).
ore throat, cough
vnetje žrela ali grla, kašelj
ore throat, cough, stuffy nose
vneto grlo, kašelj, zamašen nos
ore throat, coughing, acute breathing problems
vneto žrelo, kašelj, akutne težave z dihanjem
ore throat, hoarse voice, problems with your voice
vneto žrelo, hripav glas, težave z glasom
ore throat, runny nose, cough,
vneto žrelo, izcedek iz nosu, kašelj
ore throat, runny nose, nasal congestion and sneezing
vneto grlo oziroma žrelo, izcedek iz nosu, kongestija nosne sluznice in kihanje
ore throat, tonsillitis (pharyngitis, laryngitis)
vneto žrelo, tonzilitis (faringitis, laringitis)
ore throat.
vnetje žrela in grla
Orencia (which contains abatacept).
Orencia (ki vsebuje abatacept).
ORENCIA 125 mg solution for injection in pre-filled pen abatacept
ORENCIA 125 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku abatacept
ORENCIA 125 mg solution for injection in pre-filled pen.
ORENCIA 125 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku
ORENCIA 125 mg solution for injection in pre-filled syringe abatacept
ORENCIA 125 mg raztopina za injiciranje v napolnjeni injekcijski brizgi abatacept
ORENCIA 125 mg solution for injection in pre-filled syringe.
ORENCIA 125 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
ORENCIA 250 mg powder for concentrate for solution for infusion abatacept
ORENCIA 250 mg prašek za koncentrat za raztopino za infundiranje abatacept
ORENCIA 250 mg powder for concentrate for solution for infusion.
ORENCIA 250 mg prašek za koncentrat za raztopino za infundiranje
ORENCIA and older people
Zdravilo ORENCIA in starostniki
ORENCIA can be used by people over 65 with no change in dose.
Pri osebah, starejših od 65 let, odmerka zdravila ORENCIA ni treba spreminjati.
Orencia given by infusion can be used for both rheumatoid and juvenile idiopathic arthritis.
Zdravilo Orencia, ki se daje z infundiranjem, se lahko uporablja za revmatoidni artritis in juvenilni idiopatski artritis.
Orencia given by injection under the skin to patients with rheumatoid arthritis showed a similar benefit to Orencia given by infusion.
Zdravilo Orencia, ki se je bolnikom z revmatoidnim artritisom dajalo kot injekcija v podkožje, je izkazalo podobne koristi kot zdravilo Orencia, ki se daje z infundiranjem.
ORENCIA has been studied in 190 paediatric patients, 6 to 17 years of age, with polyarticular JIA (see section 5.1).
Uporabo zdravila ORENCIA so raziskovali pri 190 pediatričnih bolnikih s poliartikularnim juvenilnim idiopatskim artritisom, starih od 6 do 17 let (glejte poglavje 5.1).
ORENCIA has not been studied in patients under 6 years of age, therefore ORENCIA is not recommended in this patient population.
Zdravilo ORENCIA pri bolnikih, mlajših od 6 let, ni bilo raziskano, zato uporabe zdravila ORENCIA pri tej skupini bolnikov ne priporočamo.
ORENCIA increases the risk of getting infections.
Zdravilo ORENCIA povečuje tveganje za okužbe.
Orencia is a medicine that contains the active substance abatacept.
Orencia je zdravilo, ki vsebuje zdravilno učinkovino abatacept.
ORENCIA is used in children and adolescents aged 6 to 17 years after another group of medicines called TNF blockers.
Zdravilo ORENCIA uporabljamo za zdravljenje otrok in mladostnikov, starih od 6 do 17 let, po zdravljenju z zdravili iz skupine zaviralcev TNF.
Orencia is used in combination with methotrexate (a medicine that acts on the immune system) to treat the following diseases: moderate to severe active rheumatoid arthritis (an immune system disease causing damage and inflammation in the joints) in adults who have not had an adequate response to other medicines including methotrexate or a ‘tumour necrosis factor (TNF) blocker’;
Zdravilo Orencia se uporablja skupaj z metotreksatom (zdravilom, ki učinkuje na imunski sistem) za zdravljenje naslednjih bolezni: zmernega do hudega aktivnega revmatoidnega artritisa (bolezni imunskega sistema, ki povzroča poškodbe in vnetje sklepov) pri odraslih, ki se niso ustrezno odzvali na druga zdravila, med drugim na metotreksat ali na „zaviralec tumorje nekrotizirajočega faktorja (TNF)“;
ORENCIA is used to treat Rheumatoid arthritis in adults.
Zdravilo ORENCIA uporabljamo za zdravljenje revmatoidnega artritisa pri odraslih.
ORENCIA is used to:
Zdravilo ORENCIA uporabljamo za:
ORENCIA IV PATIENT ALERT CARD TEXT
ZDRAVILO ORENCIA ZA INTRAVENSKO UPORABO BESEDILO OPOZORILNE KARTICE ZA BOLNIKA
Orencia must not be used in patients with severe and uncontrolled infections, such as sepsis (when bacteria and their toxins circulate in the blood and start to damage the organs) or ‘opportunistic’ infections (infections seen in patients with a weakened immune system).
Zdravilo Orencia se ne sme uporabljati pri bolnikih s hudimi nenadzorovanimi okužbami, kot so npr. sepsa (pri kateri bakterije in njihovi toksini krožijo v krvi in povzročajo poškodbe organov) ali oportunistične okužbe (opažene pri bolnikih z oslabljenim imunskim sistemom).
ORENCIA Patient Alert Card
ORENCIA – Opozorilna kartica za bolnika
ORENCIA selectively modulates the activation of T cells involved in the immune systems’ inflammatory response.
Zdravilo ORENCIA selektivno uravnava aktivacijo celic T. Celice T sodelujejo pri vnetnem odzivu imunskega sistema.
ORENCIA should be administered as a 30-minute intravenous infusion.
Zdravilo ORENCIA je treba dati v obliki 30-minutne intravenske infuzije.
ORENCIA should be given to you again, 2 and then 4 weeks after the first infusion.
Zdravilo ORENCIA morate ponovno prejeti čez 2 in 4 tedne po prvi infuziji.
ORENCIA should not be used in pregnant women unless clearly necessary.
Zdravila ORENCIA ne smete uporabljati pri nosečnicah, razen če je nujno potrebno.
ORENCIA solution for injection (injection) is a clear, colourless to pale yellow solution provided in a pre-filled pen called ClickJect.
ORENCIA raztopina za injiciranja (injekcija) je bistra, brezbarvna do bledo rumena raztopina v napolnjenem injekcijskem peresniku, imenovanem ClickJect.
ORENCIA solution for injection (injection) is a clear, colourless to pale yellow solution.
ORENCIA raztopina za injiciranja (injekcija) je bistra, brezbarvna do bledo rumena raztopina.
ORENCIA subcutaneous (SC) may be initiated with or without an intravenous (IV) loading dose.
Subkutano (s.c.) zdravljenje z zdravilom ORENCIA se lahko uvede z intravenskim (i.v.) polnilnim odmerkom ali brez njega.
ORENCIA, in combination with methotrexate, is indicated for: the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor. the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
Zdravilo ORENCIA je v kombinaciji z metotreksatom indicirano za: zdravljenje zmernega do hudega aktivnega revmatoidnega artritisa (RA) pri odraslih bolnikih z nezadostnim odzivom na predhodno zdravljenje z enim ali več zdravili iz skupine imunomodulirajočih protirevmatičnih zdravil (DMARDs-disease-modifying anti-rheumatic drugs), vključno z metotreksatom (MTX) ali zaviralcem tumorje nekrotizirajočega faktorja-alfa (TNF-alpha-tumour necrosis factor-alpha inhibitor). zdravljenje močno aktivne in progresivne bolezni pri odraslih bolnikih z revmatoidnim artritisom, ki se predhodno še niso zdravili z metotreksatom.
oreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)
boleča ali otekla sluznica prebavnega trakta, ki poteka od ust do zadnjika (vnetje sluznice)
oreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)
občutljivost in otekanje sluznice prebavil, ki poteka od ust do zadnjika (sluznično vnetje)
oreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)
občutljivost in zatekanje sluznice prebavnega trakta, ki poteka od ust do zadnjika (vnetje sluznice)
ores in mouth, scaling lips and clefts in the corners of the mouth, rash, redness of skin, itching, eczema (inflamed, red, itchy and dryness of the skin with possible oozing lesions), acne, back pain, muscle and bone pain, limb pain, dryness, pain, rash, irritation or itching at the site of injection.
ranice v ustih, luščenje ustnic in razpoke v ustnih kotičkih, izpuščaj, pordelost kože, srbenje, ekcem (vneta, rdeča, srbeča in suha koža z morebitnimi spremembami z izcedkom), akne, bolečine v hrbtu, mišične in kostne bolečine, bolečine v udih, suhost, bolečine, izpuščaj, draženje ali srbenje na mestu injiciranja.
ores in the mouth
razjede v ustih
ores in the mouth
razjede v ustih,
ores in the mouth
razjede v ustih;
ores in the mouth
vnetje v ustni votlini;
ores in the mouth and the tube from the mouth to the stomach, which may be painful and cause difficulty swallowing,
vnetje v ustih in cevi med usti in želodcem, ki je lahko boleče in povzroča težave pri požiranju,
ores or ulcers in the mouth, diarrhoea, stomach pain, heartburn, difficulty swallowing, dry mouth
razjede ali rane v ustih, driska, bolečine v želodcu, zgaga, težave s požiranjem, suha usta
Orfadin 2 mg hard capsules Orfadin 5 mg hard capsules Orfadin 10 mg hard capsules Orfadin 20 mg hard capsules Nitisinone
Orfadin 2 mg trde kapsule Orfadin 5 mg trde kapsule Orfadin 10 mg trde kapsule Orfadin 20 mg trde kapsule nitizinon
Orfadin has minor influence on the ability to drive and use machines.
Zdravilo Orfadin ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Orfadin is also available in 2 mg, 5 mg, 10mg and 20 mg capsules, if considered more suitable for the patient.
Zdravilo Orfadin je na voljo tudi v obliki 2 mg, 5 mg, 10 mg in 20 mg kapsul, če je to za bolnika bolj ustrezno.
Orfadin was originally authorised under ‘exceptional circumstances’, because, as the disease is rare, limited information was available at the time of the approval.
Zdravilo je pridobilo dovoljenje za promet v izjemnih okoliščinah, saj so bile zaradi redkosti bolezni ob izdaji dovoljenja na voljo le omejene informacije.
Orgalutran contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially ‘sodium-free’.
Zdravilo Orgalutran vsebuje manj kot 1 mmol (23 mg) natrija na injekcijo, kar v bistvu pomeni ‘brez natrija’.
Orgalutran contains sodium
Zdravilo Orgalutran vsebuje natrij
Orgalutran contains the active substance ganirelix and belongs to a group of medicines called “anti- gonadotrophin-releasing hormones” which act against the actions of the natural gonadotrophin releasing hormone (GnRH).
Zdravilo Orgalutran vsebuje zdravilno učinkovino ganireliks in spada v skupino antagonistov gonadotropin sproščujočih hormonov, ki delujejo tako, da nasprotujejo delovanju naravnega gonadotropin sproščujočega hormona (GnRH).
Orgalutran is a clear and colourless aqueous solution for injection.
Zdravilo Orgalutran je bistra in brezbarvna vodna raztopina za injiciranje.
Organ Class
Organski sistem
Organ Class
Organski sistemi
Organ doses (mGy/MBq injected) and effective dose (Sv/GBq injected).
Doze po organih (injicirana aktivnost mGy/MBq) in efektivna doza (injicirani Sv/GBq)
Organ systems
Organski sistem
Organ transplant
Presaditev organov
Organ transplant patients
Bolniki po presaditvi organov
Organ uptake
Privzem v organe
Organ uptake
Privzem v organih
Organ uptake
Privzemanje v organih
Organic anion transporting polypeptide (OATP) inhibitors
Zaviralci polipeptidnega prenašalca organskih anionov
Organic anion transporting polypeptide (OATP) inhibitors
Zaviralci transportnega polipeptida za organske anione
Organic anion transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA’s disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides’ biliary excretion.
Izoencimi OATP, MRP2 in protein odpornosti pri raku dojk (BCRP) so prenašalci, povezani z izločanjem glukuronidov z žolčem.
Organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA’s disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides’ biliary excretion.
Izoencimi OATP, MRP2 in protein odpornosti pri raku dojk (BCRP) so prenašalci, povezani z izločanjem glukuronidov z žolčem.
Organisation of home infusion/preparation of infusion;
organiziranje infuzij na domu/priprava infuzij;
Organisation: Home environment/Caregiver/Treating physician;
organizacija: domače okolje/negovalec/lečeči zdravnik;
organisms in patients
bakterijami pri
Organon (Ireland) Limited Drynam Road
Izdelovalec Organon (Ireland) Limited Drynam Road
Organon (Ireland) Ltd,
Organon (Ireland) Ltd
Orient the needle away from you and others.
Iglo obrnite proč od sebe in drugih.
orientation, depression, anxiety symptoms, hallucination, mental disorders, depressed mood, mood disorders and disturbances, nightmare
depresija, simptomi anksioznosti, halucinacije, duševne motnje, potrtost, motnje razpoloženja, nočne more
Origin Line 1 cm from Bottom
Listič Whatman Grade 1, 3MM, 31ET Chromatography strip
Originally, in 3 studies (one comparative vs fluconazole, two non-comparative) 204 patients were studied; the mean duration of intravenous treatment in these patients was 13.5 days (range, 1 to 38 days) and 119 patients received ≥ 14 days of anidulafungin.
Prvotno so v treh študijah (eni primerjalni s flukonazolom in dveh neprimerjalnih) proučevali 204 bolnike; intravensko zdravljenje teh bolnikov je v povprečju trajalo 13,5 dneva (razpon: od 1 do 38 dni), 119 bolnikov pa je dobivalo anidulafungin ≥ 14 dni.
orised
promet a
orised orised
omet omet
Oritavancin binds to and prevents the action of the phospholipid reagents which activate coagulation in commonly used laboratory coagulation tests.
Oritavancin se veže na fosfolipidne reagente, ki aktivirajo koagulacijo pri pogosto uporabljenih laboratorijskih testih koagulacije, in preprečuje njihovo delovanje.
Oritavancin concentrations achieved in the blood after 1200 mg doses may produce falsely elevated results from certain laboratory tests (see Table 1).
Koncentracije oritavancina v krvi po 1200 mg odmerkih lahko povzročijo lažno povišane rezultate nekaterih laboratorijskih testov (glejte preglednico 1).
Oritavancin concentrations that are found in the blood of patients following administration of a single dose have been shown to artificially prolong: aPTT for up to 120 hours,
Izkazalo se je, da koncentracije oritavancina v krvi bolnikov po aplikaciji enkratnega odmerka umetno podaljšajo: aPTT za do 120 ur,
Oritavancin exhibits reduced in vitro activity against certain Gram-positive organisms of the genera
In vitro kaže oritavancin zmanjšano aktivnost proti nekaterim grampozitivnim organizmom iz rodov
Oritavancin has a minor influence on the ability to drive and use machines.
Oritavancin ima blag vpliv na sposobnost vožnje in upravljanja s stroji.